 Patients must have 1 or more of the following features: never smoker or smoking history of 15 pack years andor features of bronchioloalveolar lung cancer. 50 patients will be enrolled on this study. Treatment will be with gefitinib for at least 21 days before surgery depending on the timing of the surgery. Patients will discontinue gefitinib 2 days before their operation. For patients that demonstrate a radiographic response to gefitinib preoperatively and or patients with mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified from the surgical sample, gefitinib will continue for 2 years post-surgery. Patients who do not have evidence of radiographic response or mutations in the protein-tyrosine kinase domain of the EGF receptor gene will be removed from the study. 